This Month in Psychopharmacology

FDA Expands Flibanserin Approval to Postmenopausal Women With Hypoactive Sexual Desire Disorder

The FDA has recently granted expanded approval for flibanserin to t...

Read More

Exercise Demonstrates Moderate Effects for Depression and Anxiety Across the Lifespan

A recent meta-meta-analysis examining the effects of structured exe...

Read More

Rethinking Mood Disorder Treatment with Immunometabolic Insights

While there are many stimulant and non-stimulant options targeting ...

Read More

Brain Awareness Week: March 16-22, 2026

Each March, the global community comes together to celebrate Brain ...

Read More

FDA Accepts New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension

In February 2026, Teva Pharmaceuticals announced that the FDA has a...

Read More

Ketogenic Diet Shows Modest Short-Term Benefit in Treatment-Resistant Depression

Studies have suggested that a ketogenic diet –a high-fat, low-carbo...

Read More

Long-Term Impact of Cognitive Training on Dementia Risk: 20-Year Outcomes From a Randomized Trial

In older adults, cognitive training can facilitate long-term improv...

Read More

Preinjury Antidepressant Use Does Not Appear to Worsen Clinical Outcomes after TBI

Concerns have long circulated that serotonergic antidepressants may...

Read More

FDA Approves Milsaperidone for Schizophrenia and Acute Bipolar I Disorder

The FDA has approved milsaperidone for the treatment of schizophren...

Read More

Metformin Modestly Reduces BMI in Overweight Youth With Bipolar Disorders

Second-generation antipsychotics (SGAs) are first-line pharmacologi...

Read More

Serial Intravenous Ketamine Infusions Not Superior to Usual Inpatient Care for Depression

Serial IV ketamine infusions are increasingly used off-label for tr...

Read More

Efficacy and Tolerability of Antipsychotics for Acute Schizophrenia

Antipsychotic selection in schizophrenia remains an important, high...

Read More